Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Abramowicz

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
Journal of Nephrology|January 28, 2022
Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?Rachel Hellemans, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 9, 2013
Should we treat asymptomatic bacteriuria after renal transplantation?Julien Coussement, Daniel Abramowicz
Kidney International|January 12, 2002
Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal diseaseNilufer Broeders, Daniel Abramowicz
Transplantation|April 5, 2014
In memoriam. Professor Dr Yves VanrenterghemDirk Kuypers, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Cytomegalovirus after kidney transplantation in 2020: moving towards personalized preventionRachel Hellemans, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time?Karl Martin Wissing, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 8, 2019
Cardiovascular disease in kidney transplant recipients: leave no stone unturnedSteven Van Laecke, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 10, 2010
Bortezomib: a new player in pre- and post-transplant desensitization?Anne Lemy, Michel Toungouz, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 28, 2020
New evidence shows it is time to stop unnecessary use of antibiotics in kidney transplant recipients with asymptomatic bacteriuriaJulien Coussement, Nassim Kamar, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 11, 2020
Frailty: a new comorbidity in kidney transplant candidates?Rowena Vleut, Daniel Abramowicz, Rachel Hellemans
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
Journal of Nephrology|January 28, 2022
Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?Rachel Hellemans, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 9, 2013
Should we treat asymptomatic bacteriuria after renal transplantation?Julien Coussement, Daniel Abramowicz
Kidney International|January 12, 2002
Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal diseaseNilufer Broeders, Daniel Abramowicz
Transplantation|April 5, 2014
In memoriam. Professor Dr Yves VanrenterghemDirk Kuypers, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Cytomegalovirus after kidney transplantation in 2020: moving towards personalized preventionRachel Hellemans, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time?Karl Martin Wissing, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 8, 2019
Cardiovascular disease in kidney transplant recipients: leave no stone unturnedSteven Van Laecke, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 10, 2010
Bortezomib: a new player in pre- and post-transplant desensitization?Anne Lemy, Michel Toungouz, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 28, 2020
New evidence shows it is time to stop unnecessary use of antibiotics in kidney transplant recipients with asymptomatic bacteriuriaJulien Coussement, Nassim Kamar, Daniel Abramowicz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 11, 2020
Frailty: a new comorbidity in kidney transplant candidates?Rowena Vleut, Daniel Abramowicz, Rachel Hellemans
Pageof 14